• Chloroquine BA1002: Mechanisms and Research Use

  2026-08-19

  Chloroquine is a 4-aminoquinoline research compound that raises lysosomal pH, inhibits late-stage autophagic flux, and modulates inflammatory and survival pathways. BA1002 is suited to malaria, rheumatoid arthritis, autophagy, Toll-like receptor, antiviral, and cancer research, but in-vitro activity and research concentrations do not establish clinical efficacy or dosing.

• Pharmacological Chaperones Rescue GABAA Epilepsy Variants

  2026-08-19

  This 2024 study shows that several epilepsy-associated GABAA receptor α1 variants are loss-of-function proteins whose defects arise largely from impaired folding, assembly, and surface trafficking. The positive allosteric modulators Hispidulin and TP003 acted as client-specific pharmacological chaperones, improving receptor proteostasis and function without activating the unfolded protein response in the tested cellular models.

• Fosinopril sodium Workflows for ACE Inhibition

  2026-08-18

  Build reproducible ACE inhibition, vascular-function, and renal hemodynamics assays with Fosinopril sodium. This guide combines mechanism-aware compound handling with endpoint strategies inspired by a large cardiovascular outcomes trial, while clearly separating clinical evidence from bench recommendations.

• URB597: A Causal Lens on Endocannabinoid Pain

  2026-08-17

  URB597 and KDS-4103 provide a selective way to interrogate FAAH-dependent anandamide signaling rather than simply describe pain behavior. This article translates recent cannabidiol findings into assay-selection logic for neuroplasticity, neuroinflammation, and mechanistic pain research.

• Electrical Stimulation Boosts Nanoparticle Uptake

  2026-08-16

  The reference study shows that alternating-current electrical stimulation can increase magnetic nanoparticle endocytosis in cancer cells without requiring particle surface functionalization. By linking enhanced macropinocytosis to reduced F-actin content and elevated intracellular Ca2+, the work offers a potentially transferable strategy for improving magnetic hyperthermia and MRI performance.

• Recombinant Human IL-15: Applied Assays

  2026-08-15

  Build reproducible T-cell and NK-cell workflows with a tag-free, highly active cytokine designed for controlled immune stimulation. This guide connects quantitative IL-15 assays with cautious, exploratory neuroimmune studies inspired by new work on early-life adversity and oxytocin circuitry.

• Phosphatase Inhibitor Cocktail 2: Workflow Guide

  2026-08-15

  Phosphatase Inhibitor Cocktail 2 supports rapid, broad-spectrum preservation of phosphorylation in lysates destined for Western blotting, co-immunoprecipitation, pull-down, and kinase workflows. This guide combines practical 1X preparation with low-temperature handling principles inspired by recent chemical-proteomics research to improve assay consistency without overextending the evidence.

• rMeVHu191 Antitumor Effects in Breast Cancer

  2026-08-14

  Zheng et al. show that recombinant measles virus Hu191 produces multifaceted antitumor effects in breast cancer models, combining apoptosis induction, proliferation suppression, senescence, oxidative-stress changes, and altered lipid homeostasis. The study connects molecular, cellular, transcriptomic, and xenograft evidence, while also identifying questions that require further causal and translational validation.

• MAPK10–KRT16 Axis Suppresses NSCLC Metastasis

  2026-08-14

  The reference study identifies a phosphorylation-dependent MAPK10/KRT16/RNF213 pathway that limits non-small cell lung cancer metastasis by promoting KRT16 ubiquitination and proteasomal degradation. Its combination of molecular, cellular, animal, and clinical analyses provides a mechanistic framework for interpreting MAPK10 as a metastasis-suppressive biomarker rather than simply another signaling correlate.

• Scutellarin, Cathepsin D, and I/R Endothelial Rescue

  2026-08-13

  This 2025 Frontiers in Pharmacology study identifies cathepsin D–dependent restoration of autophagy-lysosomal function as a mechanism by which scutellarin protects endothelium during cardiac ischemia/reperfusion. Using rat and endothelial-cell models, the authors connect CTSD activity with improved vascular recovery, reduced oxidative and inflammatory injury, and better cardiac outcomes.

• PEO Chain Density and Uremic Toxin Adsorption

  2026-08-13

  The reference study shows that end-tethered methoxy-PEO films do not interact uniformly with retained uremic solutes: molecular structure, rather than solution abundance alone, strongly influences adsorption. Its surface-characterization and LC–MS workflow provides a useful framework for evaluating low-fouling biomaterials under kidney-disease-relevant chemical conditions.

• Ferroptosis lncRNA Signature in Pancreatic Cancer

  2026-08-12

  This study developed and externally validated a nine-lncRNA ferroptosis-related signature for estimating overall survival and immune-treatment patterns in pancreatic adenocarcinoma. Its main contribution is a reproducible computational framework that connects ferroptosis-associated transcriptional regulation with risk stratification, while also highlighting the need for prospective and functional validation.

• FAISL, Calpain-2, and FAK Stability in TNBC

  2026-08-12

  The reference study identifies FAISL as a focal adhesion kinase (FAK)-interacting long non-coding RNA that stabilizes FAK by preventing calpain-2-mediated proteolysis. Its combination of TCGA analysis, RNA immunoprecipitation sequencing, mechanistic cell experiments, and nanoparticle-delivered siRNA links RNA-dependent control of protein turnover to triple-negative breast cancer progression and metastasis.

• UK-5099 in Whole-Blood Immunometabolism

  2026-08-11

  UK-5099, also called PF-1005023, provides a practical way to test how mitochondrial pyruvate entry shapes cytokine responses, cellular energy status, and glucose handling. This guide translates a standardized whole-blood stimulation framework into an adaptable workflow with dose selection, controls, orthogonal readouts, and troubleshooting guidance.

• Bufalin–CRISPR Nanomedicine for Colorectal Cancer

  2026-08-10

  The reference study develops calcium lactate nanoparticles that co-deliver bufalin and CRISPR/Cas9 ribonucleoproteins targeting CD47 to combine cancer-cell killing with immune-microenvironment remodeling. Its multimodal design links pyroptosis, apoptosis, macrophage M1 repolarization, and enhanced phagocytosis, providing a mechanistic framework for local tumor control and systemic antitumor immunity.

444 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page